Among the 139 exudative AMD patients, 111 (80%) patients were treated with intravitreal injection of anti-VEGF agents, including Aflibercept, Ranibizumab, or Bevacizumab, during the follow-up period. This evidence concerns the gene VEGFA and age-related macular degeneration.